<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03389854</url>
  </required_header>
  <id_info>
    <org_study_id>17-001283</org_study_id>
    <nct_id>NCT03389854</nct_id>
  </id_info>
  <brief_title>Efficacy of Penile Traction Therapy Using a Novel Device</brief_title>
  <official_title>Efficacy of Penile Traction Therapy Using a Novel Device: A Controlled, Single-blinded, Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial is designed to assess the safety, dosing, and preliminary efficacy of a&#xD;
      novel penile traction device on correcting deformities relating to Peyronie's disease, a&#xD;
      condition which results in penile curvature and length loss. The trial is designed as a&#xD;
      randomized, placebo-controlled study with men randomized to receiving no therapy or penile&#xD;
      traction therapy 30 minutes once, twice, or three times daily. The study will occur over a 3&#xD;
      month period, after which an open label phase for 3 months will be conducted. Final&#xD;
      assessments for adverse effects will also be assessed at 9 months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Peyronie's disease (PD) is a fibrotic condition of the penis, affecting 1-13% of the US male&#xD;
      population. The disease results in penile curvature and significant psychosocial bother.&#xD;
      Current preferred therapies for PD include repeated penile injections with bacterial enzymes&#xD;
      and surgery. However, these therapies are expensive and in some cases result in permanent&#xD;
      reductions in penile length and sensation. Penile traction therapy (PTT) is a relatively&#xD;
      newer treatment which has been proposed as a treatment for PD with preliminary data&#xD;
      suggesting a potential role. However, currently available PTT devices are primarily designed&#xD;
      for penile lengthening and have many significant limitations including a requirement of use&#xD;
      for 9 hours daily and significant difficulties in personal application. Given these&#xD;
      limitations, a new penile traction device (RestoreXÂ® ) was created and funded through Mayo&#xD;
      Ventures and was specifically designed to treat men with PD. The primary objective of the&#xD;
      current study is to evaluate safety of the device using various dosing schedules, with&#xD;
      secondary endpoints designed to assess efficacy and subjective outcomes. To accomplish the&#xD;
      study, a population of men from Mayo Clinic with PD will be enrolled and will be randomized&#xD;
      to utilize the device for varying amounts of time. Outcomes will be assessed at 3, 6, and 9&#xD;
      months, and results are to be used with the intent to publish in a scientific journal.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2, 2017</start_date>
  <completion_date type="Actual">June 4, 2019</completion_date>
  <primary_completion_date type="Actual">June 4, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <intervention_model_description>Men will be randomized into one of four groups: no traction therapy, penile traction 30 minutes once daily, penile traction 30 minutes twice daily, and penile traction 30 minutes three times daily. This treatment will continue for 3 months, after which men will enter an open label phase for 3 months. Primary and secondary outcomes will be evaluated at the completion of the 3 month and 6 month time points. Additional AEs will be assessed at 9 months after study initiation.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
    <masking_description>Objective outcomes including penile length and curvature will be masked for the investigator and outcome assessor by obtaining photographs of the penis in the lateral and dorsal planes. Curvatures will also be assessed by a clinician in the case where photographs are not able to be obtained or if the participant refuses photographs. These will be assessed without any knowledge as to which grouping the patient is located by two independent reviewers. If there are differences &gt;5 degrees (curvature), or 0.5 cm (length), a 3rd individual will mediate the difference.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events at Baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>Percentage of participants being treated with penile traction to experience adverse events relating to device use defined by redness, pain, swelling, new bumps, discoloration, sensation loss, abnormal sensation or other</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events at 3 Months</measure>
    <time_frame>3 months</time_frame>
    <description>Percentage of participants being treated with penile traction to experience adverse events relating to device use defined by redness, pain, swelling, new bumps, discoloration, sensation loss, abnormal sensation or other</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events at 6 Months</measure>
    <time_frame>6 months</time_frame>
    <description>Percentage of participants being treated with penile traction to experience adverse events relating to device use defined by redness, pain, swelling, new bumps, discoloration, sensation loss, abnormal sensation or other</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events at 9 Months</measure>
    <time_frame>9 months</time_frame>
    <description>Percentage of participants being treated with penile traction to experience adverse events relating to device use defined by redness, pain, swelling, new bumps, discoloration, sensation loss, abnormal sensation or other</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Penile Length to Corona</measure>
    <time_frame>3 months, 6 months</time_frame>
    <description>Stretched penile length measured in centimeters from pubic symphysis to glanular corona</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Penile Length to Tip</measure>
    <time_frame>3 months, 6 months</time_frame>
    <description>Stretched penile length measured in centimeters from pubic symphysis to penile tip</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Penile Curvature</measure>
    <time_frame>3 months, 6 months</time_frame>
    <description>Subjects received Trimix to achieve pharmacological erection and curvature was measured in degrees. A negative result denotes an improvement in curvature.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change Erectile Function</measure>
    <time_frame>3 months, 6 months</time_frame>
    <description>Self reported International Index of Erectile Function (IIEF) questionnaire for erectile dysfunction (ED) scored on a scale of &lt;11 severe ED, 11-16 moderate ED, 17-25 mild ED, 26-30 no ED. Questionnaires were given to participants at baseline, 3 months and 6 months. Change in the score was reported for 3 months and 6 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Peyronie's Disease Psychological and Physical Domain on Peyronie's Disease Questionnaire (PDQ)</measure>
    <time_frame>Baseline, 3 months</time_frame>
    <description>Self reported Peyronie's Disease questionnaire (physical and psychological) severity score range 0 (none) to 4 (very severe) on 6 questions with a total score range 0 to 24. Negative denotes improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Peyronie's Disease Penile Pain Domain on Peyronie's Disease Questionnaire (PDQ)</measure>
    <time_frame>Baseline, 3 months</time_frame>
    <description>Self reported Peyronie's Disease questionnaire penile pain scale range 0 (no pain) and 10 (extreme pain) on 3 questions with a total score range 0 to 30. Negative denotes improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Peyronie's Disease Bother Domain of the Peyronie's Disease Questionnaire (PDQ)</measure>
    <time_frame>Baseline, 3 month</time_frame>
    <description>Self reported Peyronie's Disease questionnaire bother score range 0 (no issue or not at all bothered) and 4 (extremely bothered) on 4 questions with a total score range 0 to 16. Negative denotes improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Treatment Satisfaction</measure>
    <time_frame>3 months</time_frame>
    <description>Self reported satisfaction of penile traction therapy on a scale of very satisfied, somewhat satisfied, neutral, somewhat dissatisfied, very dissatisfied</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ability to Achieve Sexual Intercourse</measure>
    <time_frame>3 months</time_frame>
    <description>Change from no to yes on the self reported standardized sexual encounter profile questions 2 &quot;able to penetrate&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction With the RestoreXÂ® Device to Alternative Forms of PTT</measure>
    <time_frame>3 months</time_frame>
    <description>Self reported satisfaction with how RestoreXÂ® compares to other devices on a scale of much better, somewhat better, equal, somewhat worse, much worse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction With the RestoreXÂ® Device to Alternative PD Therapies</measure>
    <time_frame>3 months</time_frame>
    <description>Subjects being treated for PD the first time were asked which therapies they would choose. Respondents could select more than 1 option so values equal greater than 100%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ability to Achieve Sexual Intercourse</measure>
    <time_frame>6 months</time_frame>
    <description>Change from no to yes on the self reported standardized sexual encounter profile questions 2 &quot;able to penetrate&quot;</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Penile Diseases</condition>
  <arm_group>
    <arm_group_label>Group 1 - Control</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>No treatment will be administered for the initial 3 months. This are is necessary as Peyronie's disease may result in changes in length and curvature as a function of the disease process. After the 3 month period of time, this group will enter an open label phase where they may utilize a penile traction device if desired.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 - PTT 1x daily x 3 months</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Men will utilize penile traction therapy for 30 minutes once daily for the initial 3 months. After this phase is completed, they will enter an open label phase for 3 months where they may utilize the device as much or as little as desired.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3 - PTT 2x daily x 3 months</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Men will utilize penile traction therapy for 30 minutes twice daily for the initial 3 months. After this phase is completed, they will enter an open label phase for 3 months where they may utilize the device as much or as little as desired.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4 - PTT 3x daily x 3 months</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Men will utilize penile traction therapy for 30 minutes three times daily for the initial 3 months. After this phase is completed, they will enter an open label phase for 3 months where they may utilize the device as much or as little as desired.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RestoreX PTT - randomized and open label</intervention_name>
    <description>Penile traction therapy in the straight and bent positions</description>
    <arm_group_label>Group 2 - PTT 1x daily x 3 months</arm_group_label>
    <arm_group_label>Group 3 - PTT 2x daily x 3 months</arm_group_label>
    <arm_group_label>Group 4 - PTT 3x daily x 3 months</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RestoreX PTT - open label phase only</intervention_name>
    <description>Penile traction therapy in the straight and bent positions</description>
    <arm_group_label>Group 1 - Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of Peyronie's disease&#xD;
&#xD;
          -  Current 30 degree curvature in a single plane (i.e. 20 degrees up, 15 degrees left&#xD;
             would not be a candidate)&#xD;
&#xD;
          -  Not undergoing other therapies for PD currently&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Stretched penile length &lt;7 cm&#xD;
&#xD;
          -  Prisoners&#xD;
&#xD;
          -  Erectile dysfunction unresponsive to phosphodiesterase-5 inhibitors or intracavernosal&#xD;
             injection therapies&#xD;
&#xD;
          -  Diabetes mellitus with evidence of end-organ damage (peripheral neuropathy,&#xD;
             retinopathy, chronic kidney disease stage III or higher)&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Landon Trost, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>October 19, 2017</study_first_submitted>
  <study_first_submitted_qc>December 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">January 4, 2018</study_first_posted>
  <results_first_submitted>April 23, 2020</results_first_submitted>
  <results_first_submitted_qc>August 8, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 12, 2020</results_first_posted>
  <last_update_submitted>August 8, 2020</last_update_submitted>
  <last_update_submitted_qc>August 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Landon W. Trost</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Penile Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 9, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/54/NCT03389854/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Control Group</title>
          <description>No treatment will be administered for the initial 3 months. After the 3 month period of time, this group will enter an open label phase where they may utilize a penile traction device if desired.</description>
        </group>
        <group group_id="P2">
          <title>Penile Traction Therapy Group 1x Daily x 3 Months</title>
          <description>Men will utilize penile traction therapy for 30 minutes once daily for the initial 3 months. After this phase is completed, they will enter an open label phase for 3 months where they may utilize the device as much or as little as desired.</description>
        </group>
        <group group_id="P3">
          <title>Penile Traction Therapy Group 2x Daily x 3 Months</title>
          <description>Men will utilize penile traction therapy for 30 minutes twice daily for the initial 3 months. After this phase is completed, they will enter an open label phase for 3 months where they may utilize the device as much or as little as desired.</description>
        </group>
        <group group_id="P4">
          <title>Penile Traction Therapy Group 3x Daily x 3 Months</title>
          <description>Men will utilize penile traction therapy for 30 minutes three times daily for the initial 3 months. After this phase is completed, they will enter an open label phase for 3 months where they may utilize the device as much or as little as desired.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="28"/>
                <participants group_id="P4" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="23"/>
                <participants group_id="P4" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Control Group</title>
          <description>No treatment will be administered for the initial 3 months. After the 3 month period of time, this group will enter an open label phase where they may utilize a penile traction device if desired.</description>
        </group>
        <group group_id="B2">
          <title>Penile Traction Therapy Group 1x Daily x 3 Months</title>
          <description>Men will utilize penile traction therapy for 30 minutes once daily for the initial 3 months. After this phase is completed, they will enter an open label phase for 3 months where they may utilize the device as much or as little as desired.</description>
        </group>
        <group group_id="B3">
          <title>Penile Traction Therapy Group 2x Daily x 3 Months</title>
          <description>Men will utilize penile traction therapy for 30 minutes twice daily for the initial 3 months. After this phase is completed, they will enter an open label phase for 3 months where they may utilize the device as much or as little as desired.</description>
        </group>
        <group group_id="B4">
          <title>Penile Traction Therapy Group 3x Daily x 3 Months</title>
          <description>Men will utilize penile traction therapy for 30 minutes three times daily for the initial 3 months. After this phase is completed, they will enter an open label phase for 3 months where they may utilize the device as much or as little as desired.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
            <count group_id="B2" value="27"/>
            <count group_id="B3" value="28"/>
            <count group_id="B4" value="27"/>
            <count group_id="B5" value="110"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="28"/>
                    <count group_id="B2" value="27"/>
                    <count group_id="B3" value="28"/>
                    <count group_id="B4" value="27"/>
                    <count group_id="B5" value="110"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.1" spread="9.7"/>
                    <measurement group_id="B2" value="56.6" spread="8.3"/>
                    <measurement group_id="B3" value="59.0" spread="6.9"/>
                    <measurement group_id="B4" value="60.0" spread="5.5"/>
                    <measurement group_id="B5" value="58.4" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="28"/>
                    <count group_id="B2" value="27"/>
                    <count group_id="B3" value="28"/>
                    <count group_id="B4" value="27"/>
                    <count group_id="B5" value="110"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="27"/>
                    <measurement group_id="B5" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="28"/>
                    <count group_id="B2" value="27"/>
                    <count group_id="B3" value="28"/>
                    <count group_id="B4" value="27"/>
                    <count group_id="B5" value="110"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="27"/>
                    <measurement group_id="B5" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Adverse Events at Baseline</title>
        <description>Percentage of participants being treated with penile traction to experience adverse events relating to device use defined by redness, pain, swelling, new bumps, discoloration, sensation loss, abnormal sensation or other</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Penile Traction Therapy Group 1x Daily x 3 Months</title>
            <description>Men will utilize penile traction therapy for 30 minutes once daily for the initial 3 months. After this phase is completed, they will enter an open label phase for 3 months where they may utilize the device as much or as little as desired.</description>
          </group>
          <group group_id="O2">
            <title>Penile Traction Therapy Group 2x Daily x 3 Months</title>
            <description>Men will utilize penile traction therapy for 30 minutes twice daily for the initial 3 months. After this phase is completed, they will enter an open label phase for 3 months where they may utilize the device as much or as little as desired.</description>
          </group>
          <group group_id="O3">
            <title>Penile Traction Therapy Group 3x Daily x 3 Months</title>
            <description>Men will utilize penile traction therapy for 30 minutes three times daily for the initial 3 months. After this phase is completed, they will enter an open label phase for 3 months where they may utilize the device as much or as little as desired.</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events at Baseline</title>
          <description>Percentage of participants being treated with penile traction to experience adverse events relating to device use defined by redness, pain, swelling, new bumps, discoloration, sensation loss, abnormal sensation or other</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Penile erythema or discoloration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss or abnormal penile sensation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Adverse Events at 3 Months</title>
        <description>Percentage of participants being treated with penile traction to experience adverse events relating to device use defined by redness, pain, swelling, new bumps, discoloration, sensation loss, abnormal sensation or other</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Penile Traction Therapy Group 1x Daily x 3 Months</title>
            <description>Men will utilize penile traction therapy for 30 minutes once daily for the initial 3 months. After this phase is completed, they will enter an open label phase for 3 months where they may utilize the device as much or as little as desired.</description>
          </group>
          <group group_id="O2">
            <title>Penile Traction Therapy Group 2x Daily x 3 Months</title>
            <description>Men will utilize penile traction therapy for 30 minutes twice daily for the initial 3 months. After this phase is completed, they will enter an open label phase for 3 months where they may utilize the device as much or as little as desired.</description>
          </group>
          <group group_id="O3">
            <title>Penile Traction Therapy Group 3x Daily x 3 Months</title>
            <description>Men will utilize penile traction therapy for 30 minutes three times daily for the initial 3 months. After this phase is completed, they will enter an open label phase for 3 months where they may utilize the device as much or as little as desired.</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events at 3 Months</title>
          <description>Percentage of participants being treated with penile traction to experience adverse events relating to device use defined by redness, pain, swelling, new bumps, discoloration, sensation loss, abnormal sensation or other</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Transient Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Transient Sensory Changes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Transient Discomfort</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="50"/>
                    <measurement group_id="O3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Adverse Events at 6 Months</title>
        <description>Percentage of participants being treated with penile traction to experience adverse events relating to device use defined by redness, pain, swelling, new bumps, discoloration, sensation loss, abnormal sensation or other</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Open Label Period Penile Traction Therapy</title>
            <description>After the initial 3 month study period subjects from both the control group and the penile traction therapy group will enter an open label phase for 3 months where they may utilize the device as much or as little as desired.</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events at 6 Months</title>
          <description>Percentage of participants being treated with penile traction to experience adverse events relating to device use defined by redness, pain, swelling, new bumps, discoloration, sensation loss, abnormal sensation or other</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Penile erythema or discoloration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss or abnormal penile sensation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New penile pain, Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Adverse Events at 9 Months</title>
        <description>Percentage of participants being treated with penile traction to experience adverse events relating to device use defined by redness, pain, swelling, new bumps, discoloration, sensation loss, abnormal sensation or other</description>
        <time_frame>9 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Open Label Penile Traction Therapy</title>
            <description>After the initial 3 month study period subjects from both the control group and the penile traction therapy group will enter an open label phase for 3 months where they may utilize the device as much or as little as desired.</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events at 9 Months</title>
          <description>Percentage of participants being treated with penile traction to experience adverse events relating to device use defined by redness, pain, swelling, new bumps, discoloration, sensation loss, abnormal sensation or other</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Penile erythema or discoloration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New penile pain, Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Penile Length to Corona</title>
        <description>Stretched penile length measured in centimeters from pubic symphysis to glanular corona</description>
        <time_frame>3 months, 6 months</time_frame>
        <population>It was pre-specified to combine Penile Traction Therapy Groups for this analysis. Data for 27 subjects control group and 62 subjects PTT group available for analysis at 3 mo. Data for 14 subjects original control group and 37 subjects original PTT group available for analysis at 6 mo.</population>
        <group_list>
          <group group_id="O1">
            <title>Control Group</title>
            <description>No treatment will be administered for the initial 3 months. After the 3 month period of time, this group will enter an open label phase where they may utilize a penile traction device if desired.</description>
          </group>
          <group group_id="O2">
            <title>Penile Traction Therapy Group</title>
            <description>RestoreX for 30 minutes (15 minutes straight and 15 minutes with counter bending) once, twice or 3 times daily as Penile Traction Therapy (PTT).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Penile Length to Corona</title>
          <description>Stretched penile length measured in centimeters from pubic symphysis to glanular corona</description>
          <population>It was pre-specified to combine Penile Traction Therapy Groups for this analysis. Data for 27 subjects control group and 62 subjects PTT group available for analysis at 3 mo. Data for 14 subjects original control group and 37 subjects original PTT group available for analysis at 6 mo.</population>
          <units>Centimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3 month</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="62"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.8"/>
                    <measurement group_id="O2" value="1.3" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 month</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="1.1"/>
                    <measurement group_id="O2" value="2.3" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Control group vs Penile Traction Therapy Group at 3 months</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Control group vs Penile Traction Therapy Group at 6 months</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.90</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Penile Length to Tip</title>
        <description>Stretched penile length measured in centimeters from pubic symphysis to penile tip</description>
        <time_frame>3 months, 6 months</time_frame>
        <population>It was pre-specified to combine Penile Traction Therapy Groups for this analysis. Data for 27 subjects control group and 62 subjects PTT group available for analysis at 3 mo. Data for 14 subjects original control group and 37 subjects original PTT group available for analysis at 6 mo.</population>
        <group_list>
          <group group_id="O1">
            <title>Control Group</title>
            <description>No treatment will be administered for the initial 3 months. After the 3 month period of time, this group will enter an open label phase where they may utilize a penile traction device if desired.</description>
          </group>
          <group group_id="O2">
            <title>Penile Traction Therapy Group</title>
            <description>RestoreX for 30 minutes (15 minutes straight and 15 minutes with counter bending) once, twice or 3 times daily as Penile Traction Therapy (PTT).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Penile Length to Tip</title>
          <description>Stretched penile length measured in centimeters from pubic symphysis to penile tip</description>
          <population>It was pre-specified to combine Penile Traction Therapy Groups for this analysis. Data for 27 subjects control group and 62 subjects PTT group available for analysis at 3 mo. Data for 14 subjects original control group and 37 subjects original PTT group available for analysis at 6 mo.</population>
          <units>Centimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="62"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.7"/>
                    <measurement group_id="O2" value="1.5" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="1.2"/>
                    <measurement group_id="O2" value="1.9" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Control group vs Penile Traction Therapy Group at 3 months</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Control group vs. Penile Traction Therapy Group at 6 months</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.40</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Penile Curvature</title>
        <description>Subjects received Trimix to achieve pharmacological erection and curvature was measured in degrees. A negative result denotes an improvement in curvature.</description>
        <time_frame>3 months, 6 months</time_frame>
        <population>It was pre-specified to combine Penile Traction Therapy Groups for this analysis. Data for 27 subjects control group and 62 subjects PTT group available for analysis at 3 mo. Data for 14 subjects original control group and 37 subjects original PTT group available for analysis at 6 mo.</population>
        <group_list>
          <group group_id="O1">
            <title>Control Group</title>
            <description>No treatment will be administered for the initial 3 months. After the 3 month period of time, this group will enter an open label phase where they may utilize a penile traction device if desired.</description>
          </group>
          <group group_id="O2">
            <title>Penile Traction Therapy Group</title>
            <description>RestoreX for 30 minutes (15 minutes straight and 15 minutes with counter bending) once, twice or 3 times daily as Penile Traction Therapy (PTT).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Penile Curvature</title>
          <description>Subjects received Trimix to achieve pharmacological erection and curvature was measured in degrees. A negative result denotes an improvement in curvature.</description>
          <population>It was pre-specified to combine Penile Traction Therapy Groups for this analysis. Data for 27 subjects control group and 62 subjects PTT group available for analysis at 3 mo. Data for 14 subjects original control group and 37 subjects original PTT group available for analysis at 6 mo.</population>
          <units>degrees</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="62"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="19.0"/>
                    <measurement group_id="O2" value="-11.7" spread="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.5" spread="18.6"/>
                    <measurement group_id="O2" value="-14.9" spread="18.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Control group vs Penile Traction Therapy Group at 3 months</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.01</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Control group vs. Penile Traction Therapy Group at 6 months</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.64</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change Erectile Function</title>
        <description>Self reported International Index of Erectile Function (IIEF) questionnaire for erectile dysfunction (ED) scored on a scale of &lt;11 severe ED, 11-16 moderate ED, 17-25 mild ED, 26-30 no ED. Questionnaires were given to participants at baseline, 3 months and 6 months. Change in the score was reported for 3 months and 6 months.</description>
        <time_frame>3 months, 6 months</time_frame>
        <population>It was pre-specified to combine Penile Traction Therapy Groups for this analysis. Questionnaire 26 subjects control group and 59 subjects PTT group available for analysis 3 mo. Questionnaire 14 subjects original control group and 37 subjects original PTT group available for analysis 6 mo.</population>
        <group_list>
          <group group_id="O1">
            <title>Control Group</title>
            <description>No treatment will be administered for the initial 3 months. After the 3 month period of time, this group will enter an open label phase where they may utilize a penile traction device if desired.</description>
          </group>
          <group group_id="O2">
            <title>Penile Traction Therapy Group</title>
            <description>RestoreX for 30 minutes (15 minutes straight and 15 minutes with counter bending) once, twice or 3 times daily as Penile Traction Therapy (PTT).</description>
          </group>
        </group_list>
        <measure>
          <title>Change Erectile Function</title>
          <description>Self reported International Index of Erectile Function (IIEF) questionnaire for erectile dysfunction (ED) scored on a scale of &lt;11 severe ED, 11-16 moderate ED, 17-25 mild ED, 26-30 no ED. Questionnaires were given to participants at baseline, 3 months and 6 months. Change in the score was reported for 3 months and 6 months.</description>
          <population>It was pre-specified to combine Penile Traction Therapy Groups for this analysis. Questionnaire 26 subjects control group and 59 subjects PTT group available for analysis 3 mo. Questionnaire 14 subjects original control group and 37 subjects original PTT group available for analysis 6 mo.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="6.7"/>
                    <measurement group_id="O2" value="2.5" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="4.4"/>
                    <measurement group_id="O2" value="4.4" spread="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Control group vs Penile Traction Therapy Group at 3 months</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.06</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Control group vs Penile Traction Therapy Group at 6 months</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.66</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Peyronie's Disease Psychological and Physical Domain on Peyronie's Disease Questionnaire (PDQ)</title>
        <description>Self reported Peyronie's Disease questionnaire (physical and psychological) severity score range 0 (none) to 4 (very severe) on 6 questions with a total score range 0 to 24. Negative denotes improvement.</description>
        <time_frame>Baseline, 3 months</time_frame>
        <population>It was pre-specified to combine Penile Traction Therapy Groups for this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Control Group</title>
            <description>No treatment will be administered for the initial 3 months. After the 3 month period of time, this group will enter an open label phase where they may utilize a penile traction device if desired.</description>
          </group>
          <group group_id="O2">
            <title>Penile Traction Therapy Group</title>
            <description>RestoreX for 30 minutes (15 minutes straight and 15 minutes with counter bending) once, twice or 3 times daily as Penile Traction Therapy (PTT).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Peyronie's Disease Psychological and Physical Domain on Peyronie's Disease Questionnaire (PDQ)</title>
          <description>Self reported Peyronie's Disease questionnaire (physical and psychological) severity score range 0 (none) to 4 (very severe) on 6 questions with a total score range 0 to 24. Negative denotes improvement.</description>
          <population>It was pre-specified to combine Penile Traction Therapy Groups for this analysis.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="3.3"/>
                    <measurement group_id="O2" value="-2.3" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.09</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Peyronie's Disease Penile Pain Domain on Peyronie's Disease Questionnaire (PDQ)</title>
        <description>Self reported Peyronie's Disease questionnaire penile pain scale range 0 (no pain) and 10 (extreme pain) on 3 questions with a total score range 0 to 30. Negative denotes improvement.</description>
        <time_frame>Baseline, 3 months</time_frame>
        <population>It was pre-specified to combine Penile Traction Therapy Groups for this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Control Group</title>
            <description>No treatment will be administered for the initial 3 months. After the 3 month period of time, this group will enter an open label phase where they may utilize a penile traction device if desired.</description>
          </group>
          <group group_id="O2">
            <title>Penile Traction Therapy Group</title>
            <description>RestoreX for 30 minutes (15 minutes straight and 15 minutes with counter bending) once, twice or 3 times daily as Penile Traction Therapy (PTT).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Peyronie's Disease Penile Pain Domain on Peyronie's Disease Questionnaire (PDQ)</title>
          <description>Self reported Peyronie's Disease questionnaire penile pain scale range 0 (no pain) and 10 (extreme pain) on 3 questions with a total score range 0 to 30. Negative denotes improvement.</description>
          <population>It was pre-specified to combine Penile Traction Therapy Groups for this analysis.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="3.6"/>
                    <measurement group_id="O2" value="-1.4" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.26</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Peyronie's Disease Bother Domain of the Peyronie's Disease Questionnaire (PDQ)</title>
        <description>Self reported Peyronie's Disease questionnaire bother score range 0 (no issue or not at all bothered) and 4 (extremely bothered) on 4 questions with a total score range 0 to 16. Negative denotes improvement.</description>
        <time_frame>Baseline, 3 month</time_frame>
        <population>It was pre-specified to combine Penile Traction Therapy Groups for this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Control Group</title>
            <description>No treatment will be administered for the initial 3 months. After the 3 month period of time, this group will enter an open label phase where they may utilize a penile traction device if desired.</description>
          </group>
          <group group_id="O2">
            <title>Penile Traction Therapy Group</title>
            <description>RestoreX for 30 minutes (15 minutes straight and 15 minutes with counter bending) once, twice or 3 times daily as Penile Traction Therapy (PTT).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Peyronie's Disease Bother Domain of the Peyronie's Disease Questionnaire (PDQ)</title>
          <description>Self reported Peyronie's Disease questionnaire bother score range 0 (no issue or not at all bothered) and 4 (extremely bothered) on 4 questions with a total score range 0 to 16. Negative denotes improvement.</description>
          <population>It was pre-specified to combine Penile Traction Therapy Groups for this analysis.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="4.2"/>
                    <measurement group_id="O2" value="-2.4" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.07</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Treatment Satisfaction</title>
        <description>Self reported satisfaction of penile traction therapy on a scale of very satisfied, somewhat satisfied, neutral, somewhat dissatisfied, very dissatisfied</description>
        <time_frame>3 months</time_frame>
        <population>It was pre-specified to combine Penile Traction Therapy Groups for this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Penile Traction Therapy Group</title>
            <description>RestoreX for 30 minutes (15 minutes straight and 15 minutes with counter bending) once, twice or 3 times daily as Penile Traction Therapy (PTT).</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Treatment Satisfaction</title>
          <description>Self reported satisfaction of penile traction therapy on a scale of very satisfied, somewhat satisfied, neutral, somewhat dissatisfied, very dissatisfied</description>
          <population>It was pre-specified to combine Penile Traction Therapy Groups for this analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>% Very Satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% Somewhat satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% Neutral</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% Somewhat dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% Very dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ability to Achieve Sexual Intercourse</title>
        <description>Change from no to yes on the self reported standardized sexual encounter profile questions 2 &quot;able to penetrate&quot;</description>
        <time_frame>3 months</time_frame>
        <population>It was pre-specified to combine Penile Traction Therapy Groups for this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Control Group</title>
            <description>No treatment will be administered for the initial 3 months. After the 3 month period of time, this group will enter an open label phase where they may utilize a penile traction device if desired.</description>
          </group>
          <group group_id="O2">
            <title>Penile Traction Therapy Group</title>
            <description>RestoreX for 30 minutes (15 minutes straight and 15 minutes with counter bending) once, twice or 3 times daily as Penile Traction Therapy (PTT).</description>
          </group>
        </group_list>
        <measure>
          <title>Ability to Achieve Sexual Intercourse</title>
          <description>Change from no to yes on the self reported standardized sexual encounter profile questions 2 &quot;able to penetrate&quot;</description>
          <population>It was pre-specified to combine Penile Traction Therapy Groups for this analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Satisfaction With the RestoreXÂ® Device to Alternative Forms of PTT</title>
        <description>Self reported satisfaction with how RestoreXÂ® compares to other devices on a scale of much better, somewhat better, equal, somewhat worse, much worse</description>
        <time_frame>3 months</time_frame>
        <population>It was pre-specified to combine Penile Traction Therapy Groups for this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Penile Traction Therapy Group</title>
            <description>RestoreX for 30 minutes (15 minutes straight and 15 minutes with counter bending) once, twice or 3 times daily as Penile Traction Therapy (PTT).</description>
          </group>
        </group_list>
        <measure>
          <title>Satisfaction With the RestoreXÂ® Device to Alternative Forms of PTT</title>
          <description>Self reported satisfaction with how RestoreXÂ® compares to other devices on a scale of much better, somewhat better, equal, somewhat worse, much worse</description>
          <population>It was pre-specified to combine Penile Traction Therapy Groups for this analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>% RestoreX is much better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% RestoreX is somewhat better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% Both are equal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% RestoreX is somewhat worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% RestoreX is much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Satisfaction With the RestoreXÂ® Device to Alternative PD Therapies</title>
        <description>Subjects being treated for PD the first time were asked which therapies they would choose. Respondents could select more than 1 option so values equal greater than 100%.</description>
        <time_frame>3 months</time_frame>
        <population>It was pre-specified to combine Penile Traction Therapy Groups for this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Penile Traction Therapy Group</title>
            <description>RestoreX for 30 minutes (15 minutes straight and 15 minutes with counter bending) once, twice or 3 times daily as Penile Traction Therapy (PTT).</description>
          </group>
        </group_list>
        <measure>
          <title>Satisfaction With the RestoreXÂ® Device to Alternative PD Therapies</title>
          <description>Subjects being treated for PD the first time were asked which therapies they would choose. Respondents could select more than 1 option so values equal greater than 100%.</description>
          <population>It was pre-specified to combine Penile Traction Therapy Groups for this analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RestoreX</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Collagenase clostridium histolyticum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oral pills</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vacuum erection device</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other therapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other traction device</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ability to Achieve Sexual Intercourse</title>
        <description>Change from no to yes on the self reported standardized sexual encounter profile questions 2 &quot;able to penetrate&quot;</description>
        <time_frame>6 months</time_frame>
        <population>It was pre-specified to combine Penile Traction Therapy Groups for this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Control Group</title>
            <description>No treatment will be administered for the initial 3 months. After the 3 month period of time, this group will enter an open label phase where they may utilize a penile traction device if desired.</description>
          </group>
          <group group_id="O2">
            <title>Penile Traction Therapy Group</title>
            <description>RestoreX for 30 minutes (15 minutes straight and 15 minutes with counter bending) once, twice or 3 times daily as Penile Traction Therapy (PTT).</description>
          </group>
        </group_list>
        <measure>
          <title>Ability to Achieve Sexual Intercourse</title>
          <description>Change from no to yes on the self reported standardized sexual encounter profile questions 2 &quot;able to penetrate&quot;</description>
          <population>It was pre-specified to combine Penile Traction Therapy Groups for this analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected over a 9 month period for each subject receiving penile traction therapy.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Penile Traction Therapy Group 1x Daily x 3 Months</title>
          <description>Men will utilize penile traction therapy for 30 minutes once daily for the initial 3 months. After this phase is completed, they will enter an open label phase for 3 months where they may utilize the device as much or as little as desired.</description>
        </group>
        <group group_id="E2">
          <title>Penile Traction Therapy Group 2x Daily x 3 Months</title>
          <description>Men will utilize penile traction therapy for 30 minutes twice daily for the initial 3 months. After this phase is completed, they will enter an open label phase for 3 months where they may utilize the device as much or as little as desired.</description>
        </group>
        <group group_id="E3">
          <title>Penile Traction Therapy Group 3x Daily x 3 Months</title>
          <description>Men will utilize penile traction therapy for 30 minutes three times daily for the initial 3 months. After this phase is completed, they will enter an open label phase for 3 months where they may utilize the device as much or as little as desired.</description>
        </group>
        <group group_id="E4">
          <title>Open Label Period Penile Traction Therapy</title>
          <description>After the initial 3 month study period subjects from both the control group and the penile traction therapy group will enter an open label phase for 3 months where they may utilize the device as much or as little as desired.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="28" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Penile erythema or discoloration, transient</sub_title>
                <description>3 month outcomes among men in PTT group</description>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="27"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="28"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="27"/>
                <counts group_id="E4" events="24" subjects_affected="24" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Loss or abnormal penile sensation, transient (new onset for 6-, 9-month cohorts)</sub_title>
                <description>Total includes men who either had symptom at 6 or 9 months</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="28"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>New penile pain, transient (mild)</sub_title>
                <description>At 3 month time point (among men treated with traction)</description>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="27"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="28"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="27"/>
                <counts group_id="E4" events="19" subjects_affected="19" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Landon Trost</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>507-284-3728</phone>
      <email>Trost.Landon@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

